G Kosaki
About
In The Last Decade
G Kosaki
20 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 77
- Oncology 774
- Surgery 650
- Pulmonary and Respiratory Medicine 475
- Physiology 414
- Cancer Research 158
Countries citing papers authored by G Kosaki
This map shows the geographic impact of G Kosaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Kosaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Kosaki more than expected).
Fields of papers citing papers by G Kosaki
This network shows the impact of papers produced by G Kosaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Kosaki. The network helps show where G Kosaki may publish in the future.
Co-authorship network of co-authors of G Kosaki
This figure shows the co-authorship network connecting the top 25 collaborators of G Kosaki. A scholar is included among the top collaborators of G Kosaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Kosaki. G Kosaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | [A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation)]. | 12 |
| 2 | [Notification of cancer in breast cancer patients]. | 8 |
| 3 | [Sequential methotrexate.5FU chemotherapy for gastric cancer--comparison between intra-aortic infusion therapy and intravenous administration therapy]. | 0 |
| 4 | [Early phase II study of the combined use of AO-90 methionine-free amino acid solution and anticancer agents (5-FU and MMC) in patients with advanced and recurrent gastrointestinal cancer. AO-90 Study group]. | 3 |
| 5 | [Evaluation of postoperative immunochemotherapy in lung cancer]. | 3 |
| 6 | [Phase II study of 5'-DFUR in gastrointestinal and breast cancer]. | 1 |
| 7 | [Comparative studies of estrogen receptor determinations by enzyme immuno-assay using the monoclonal antibody, dextran-coated charcoal, and sucrose density gradient methods]. | 3 |
| 8 | [Intra-arterial infusion therapy with angiotensin II in gastric carcinoma]. | 3 |
| 9 | [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. breakdown → | 1402 |
| 10 | Sexual function after aorto-iliac vascular reconstruction. Which is more important, the internal iliac artery or hypogastric nerve? | 21 |
| 11 | [Histopathological study on hepatic metastases and blood CEA levels in patients with intestinal carcinoma]. | 3 |
| 12 | Sister chromatid exchanges in lymphocytes of a patient treated with cyclophosphamide and vincristine for non-Hodgkin's lymphoma. | 12 |
| 13 | Sexual function in patients with aortoiliac vascular disorders. | 1 |
| 14 | [Intra-arterial infusion of cancer chemotherapeutic drugs in the treatment of advanced breast cancer (author's transl)]. | 1 |
| 15 | Clinical study of haptoglobin therapy for prevention of hemoglobinuria. | 1 |
| 16 | Haptoglobin therapy: effect on prevention and treatment of hemoglobinuria. | 1 |
| 17 | Influence of flurbiprofen on platelet aggregation. I. Metabolic and ultrastructural studies in vitro. | 1 |
| 18 | [Microstructure of the platelets]. | 1 |
| 19 | [Lymphatic metastasis of gastric carcinoma]. | 1 |
| 20 | [Adjuvant immunotherapy of cancer]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.